NCIC Clinical Trials Group

NCT06235697

Phase 3Recruiting2024710 people1 Feb 2024clinicaltrials.gov

NCT06205485

Phase 3Recruiting2024250 people16 Jan 2024clinicaltrials.gov

NCT06182774

Phase 3Recruiting2024570 people27 Dec 2023clinicaltrials.gov

NCT05180097

Phase 2Recruiting202284 people6 Jan 2022clinicaltrials.gov

NCT04685616

CollaboratorPhase 3Recruiting20221,042 people28 Dec 2020clinicaltrials.gov

NCT04161248

Early phase 1Active, not recruiting202040 people13 Nov 2019clinicaltrials.gov

NCT03822897

Phase 2Active, not recruiting2019103 people30 Jan 2019clinicaltrials.gov

NCT03550391

Phase 3Recruiting2018206 people8 Jun 2018clinicaltrials.gov

NCT03488693

Phase 3Active, not recruiting20182,138 people5 Apr 2018clinicaltrials.gov

NCT03480776

Phase 2Active, not recruiting2018117 people29 Mar 2018clinicaltrials.gov

NCT03414970

CollaboratorPhase 3Active, not recruiting2018898 people30 Jan 2018clinicaltrials.gov

NCT03258554

CollaboratorPhase 2/3Completed2018196 people23 Aug 2017clinicaltrials.gov

NCT02927249

CollaboratorPhase 3Terminated20173,021 people7 Oct 2016clinicaltrials.gov

NCT02784171

Phase 2/3Completed2016520 people26 May 2016clinicaltrials.gov

NCT02597062

Phase 2Completed201676 people4 Nov 2015clinicaltrials.gov

NCT02436707

Phase 2Active, not recruiting2015129 people7 May 2015clinicaltrials.gov

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

CollaboratorPhase 3Active, not recruiting2014488 people6 Dec 2013clinicaltrials.gov

NCT01924819

CollaboratorPhase 2/3Active, not recruiting2009574 people19 Aug 2013clinicaltrials.gov

NCT01846390

Phase 1Completed201321 people3 May 2013clinicaltrials.gov

NCT01783197

Phase 1Completed201339 people4 Feb 2013clinicaltrials.gov